NO20033241D0 - Fremgangsmåte - Google Patents

Fremgangsmåte

Info

Publication number
NO20033241D0
NO20033241D0 NO20033241A NO20033241A NO20033241D0 NO 20033241 D0 NO20033241 D0 NO 20033241D0 NO 20033241 A NO20033241 A NO 20033241A NO 20033241 A NO20033241 A NO 20033241A NO 20033241 D0 NO20033241 D0 NO 20033241D0
Authority
NO
Norway
Prior art keywords
liquid
particles
temperature
substance
modulator
Prior art date
Application number
NO20033241A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033241L (no
Inventor
Goeran Eric Sundholm
Mustafa Demirbueker
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033241D0 publication Critical patent/NO20033241D0/no
Publication of NO20033241L publication Critical patent/NO20033241L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20033241A 2001-01-26 2003-07-17 Fremgangsmåte NO20033241L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102075.9A GB0102075D0 (en) 2001-01-26 2001-01-26 Process
PCT/GB2002/000261 WO2002058674A2 (en) 2001-01-26 2002-01-22 Process for preparing particles

Publications (2)

Publication Number Publication Date
NO20033241D0 true NO20033241D0 (no) 2003-07-17
NO20033241L NO20033241L (no) 2003-07-17

Family

ID=9907591

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033241A NO20033241L (no) 2001-01-26 2003-07-17 Fremgangsmåte

Country Status (21)

Country Link
US (2) US7108867B2 (de)
EP (1) EP1357901B1 (de)
JP (1) JP4175892B2 (de)
KR (1) KR100853596B1 (de)
CN (1) CN1298312C (de)
AT (1) ATE354352T1 (de)
BR (1) BR0206439A (de)
CA (1) CA2433838A1 (de)
CY (1) CY1106550T1 (de)
DE (1) DE60218285T2 (de)
DK (1) DK1357901T3 (de)
ES (1) ES2281509T3 (de)
GB (1) GB0102075D0 (de)
IL (2) IL156720A0 (de)
MX (1) MXPA03006537A (de)
NO (1) NO20033241L (de)
NZ (1) NZ526942A (de)
PT (1) PT1357901E (de)
SI (1) SI1357901T1 (de)
WO (1) WO2002058674A2 (de)
ZA (1) ZA200304953B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2006516958A (ja) * 2002-12-19 2006-07-13 バクスター・インターナショナル・インコーポレイテッド 超臨界流体を用いた組み合わせ薬学的処方物を調製するためのプロセス
JP5207432B2 (ja) * 2003-04-29 2013-06-12 エム・エス・ディー・オス・ベー・フェー アンチ溶媒凝固プロセス
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
US7220456B2 (en) 2004-03-31 2007-05-22 Eastman Kodak Company Process for the selective deposition of particulate material
US7223445B2 (en) 2004-03-31 2007-05-29 Eastman Kodak Company Process for the deposition of uniform layer of particulate material
EP1904219A4 (de) * 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
US20080187568A1 (en) * 2007-02-06 2008-08-07 Sawhney Amarpreet S Polymerization with precipitation of proteins for elution in physiological solution
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
PL2229233T3 (pl) * 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Sposób wytwarzania cząstek
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
EP4324475A1 (de) * 2012-03-22 2024-02-21 Novo Nordisk A/S Zusammensetzungen von glp-1-peptiden und herstellung davon
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6668652B2 (ja) 2015-09-18 2020-03-18 日本精工株式会社 直動案内装置、直動案内装置用エンドキャップ
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2022304547B2 (en) * 2021-06-28 2025-03-06 Micro Motion, Inc. Coriolis flow meter non-ideal fluid measurement and related methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0432232T3 (da) 1989-05-01 1994-01-31 Alkermes Inc Fremgangsmåde til fremstilling af små partikler af biologisk aktive molekyler
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
CA2326349A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
GB9828204D0 (en) 1998-12-21 1999-02-17 Smithkline Beecham Plc Process
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EP1425355A1 (de) * 2001-07-12 2004-06-09 Eastman Kodak Company Eine komprimierte flüssige zusammensetzung
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
EP1727520A2 (de) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing

Also Published As

Publication number Publication date
MXPA03006537A (es) 2003-09-22
DK1357901T3 (da) 2007-06-04
KR100853596B1 (ko) 2008-08-22
US20070009604A1 (en) 2007-01-11
CY1106550T1 (el) 2012-01-25
NO20033241L (no) 2003-07-17
CN1487825A (zh) 2004-04-07
GB0102075D0 (en) 2001-03-14
CA2433838A1 (en) 2002-08-01
WO2002058674A2 (en) 2002-08-01
DE60218285T2 (de) 2007-11-15
DE60218285D1 (de) 2007-04-05
US7108867B2 (en) 2006-09-19
PT1357901E (pt) 2007-05-31
BR0206439A (pt) 2003-12-30
AU2002225193B2 (en) 2006-07-27
NZ526942A (en) 2005-04-29
KR20030070921A (ko) 2003-09-02
JP4175892B2 (ja) 2008-11-05
EP1357901B1 (de) 2007-02-21
IL156720A0 (en) 2004-01-04
ZA200304953B (en) 2004-08-25
SI1357901T1 (sl) 2007-08-31
HK1063157A1 (en) 2004-12-17
US20040058007A1 (en) 2004-03-25
JP2004521891A (ja) 2004-07-22
US7829123B2 (en) 2010-11-09
IL156720A (en) 2010-03-28
ES2281509T3 (es) 2007-10-01
CN1298312C (zh) 2007-02-07
EP1357901A2 (de) 2003-11-05
ATE354352T1 (de) 2007-03-15
WO2002058674A3 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
GB0102075D0 (en) Process
DE60131165D1 (de) Gel auf der basis von polysacchariden
Geiser et al. In-line system containing porous polymer monoliths for protein digestion with immobilized pepsin, peptide preconcentration and nano-liquid chromatography separation coupled to electrospray ionization mass spectroscopy
ATE478107T1 (de) Verfahren zur reinigung von polyetherketone mit wasser
ATE444112T1 (de) Dispersionen von silikonen
EA200101126A1 (ru) Принудительное удаление текучей среды с помощью капиллярного пропитывания
DE60321318D1 (de) Gewinnung von delta-9 tetrahydrocannabinol
ATE349460T1 (de) Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
DK1528953T3 (da) Fremgangsmåde og anordning til stripning af ammoniak fra væsker
EP0335654A3 (de) Riechstoff bindendes Protein aus Ratten
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
Snellman et al. Haptoglobin acting as a natural inhibitor of cathepsin B activity
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
Iwata et al. Rabbit pulmonary angiotensin-converting enzyme: the NH2-terminal fragment with enzymatic activity and its formation from the native enzyme by NH4OH treatment
DE60203287D1 (de) Verfahren zur erhitzung und doppelten elektromagnetischen polarisation von flüssigem und gasförmigem brennstoff und dazugehörige vorrichtung
ATE551991T1 (de) Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
ATE374824T1 (de) Lösliche notch basierte substrate für gamma secretase, methoden, zusammensetzungen und verwendungen davon
ATE316575T1 (de) Rekombinante mistellektine
BG106842A (en) Human heparanase-related polypeptide and nucleic acid
BR9915484A (pt) Processo para o isolamento contìnuo de proteìnas ativas
Huang et al. Effects of glycine, water, ammonia, and ammonium bicarbonate on the oligomerization of methionine
KR890701754A (ko) 정제된 인돌 수용액의 제조방법
JPS53130054A (en) Orientation treatment method of liquid crystal cells
Dian et al. Overcoming protein instability problems during fusion protein cleavage
Massis Biophysical studies and thermodynamic analysis of cathepsin B interactions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application